# IRS Disputes Cannabis Company’s Tax Argument (Newsletter: March 12, 2026) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-companies-tax-disputes-irs-2026-newsletter/ > **Published:** 2026-03-12T08:52:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:24-04:00 > **Clinical Summary:** Cannabis companies tax disputes with the IRS create financial uncertainty affecting patient access and product pricing in medical cannabis markets. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryResearch Why This Matters Cannabis companies’ ongoing tax disputes with the IRS create financial uncertainty that may affect product pricing and availability for patients who depend on [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) for symptom management. Clarification of Hawaii’s [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) policies in healthcare facilities could improve clinician access to treatment guidelines and establish standardized protocols for [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) in clinical settings. Research on cannabis and sexual function outcomes provides clinicians with evidence needed to counsel patients on potential therapeutic benefits and side effects relevant to quality of life discussions. Clinical Summary The Internal Revenue Service’s dispute with cannabis companies over tax deductions highlights ongoing federal-level barriers to cannabis industry legitimacy and operational efficiency, which indirectly affects patient access and product pricing in states where medical cannabis is legal. Concurrent legislative efforts including an online safety bill and ongoing marijuana business regulation discussions signal gradual shifts toward normalizing cannabis commerce, though federal prohibition remains a structural constraint on the industry’s ability to operate transparently and invest in quality assurance. Hawaii’s integration of medical cannabis into healthcare facilities represents a state-level move toward clinical oversight and standardization that could improve dosing consistency and safety monitoring for patients. Separate research findings regarding cannabis and sexual function add to the growing body of evidence on cannabis effects beyond pain and nausea, expanding the clinical conversation about therapeutic applications and patient-reported outcomes. Collectively, these developments reflect the tension between expanding [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) and persistent federal regulatory barriers that complicate prescribing practices and limit robust clinical integration. Clinicians should remain aware that tax and regulatory barriers continue to constrain product standardization and quality control in the cannabis market, making patient education about product variability and sourcing through licensed dispensaries particularly important. Dr. Caplan’s Take “The IRS’s continued application of Section 280E to cannabis businesses artificially inflates their operating costs and pricing, which directly harms my patients who rely on medical cannabis by making effective treatment financially inaccessible, and until Congress fixes this tax code absurdity, we’ll continue seeing preventable suffering among people who could otherwise benefit from this medicine.” Clinical Perspective The ongoing tax disputes between the IRS and cannabis businesses underscore the complex intersection of federal prohibition and state-level legalization that clinicians should understand when counseling patients. While the IRS controversy primarily affects business operations rather than clinical practice directly, it reflects broader regulatory uncertainty that can impact patient access, product consistency, and pricing in legal markets. Simultaneously, state-level integration of medical cannabis into healthcare facilities—as seen in Hawaii’s initiatives—signals a gradual shift toward clinical oversight, though this creates variability in how different healthcare systems approach [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), documentation, and drug interactions. Clinicians should remain cautious about emerging claims regarding cannabis and sexual function, recognizing that while patient-reported benefits may be genuine, robust clinical evidence remains limited and confounded by factors such as symptom expectancy, underlying medical conditions, and concurrent medications. Given these intersecting policy and evidence gaps, providers caring for patients who use or are considering cannabis should stay informed about 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+IRS+disputes+cannabis+company%27s+tax+argument+%28Newsletter%3A+March+12%2C+2026%29+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Firs-disputes-cannabis-companys-tax-argument-newsletter-march-12-2026%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Firs-disputes-cannabis-companys-tax-argument-newsletter-march-12-2026%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+IRS+disputes+cannabis+company%27s+tax+argument+%28Newsletter%3A+March+12%2C+2026%29+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Firs-disputes-cannabis-companys-tax-argument-newsletter-march-12-2026%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/irs-disputes-cannabis-companys-tax-argument-newsletter-march-12-2026/](https://www.marijuanamoment.net/irs-disputes-cannabis-companys-tax-argument-newsletter-march-12-2026/) Further Reading Evidence Watch[Cannabinoid Clinical Trials: CBD Cortical Excitability Study](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [IRS Files First Response to Common Industry 280E Arguments | Harris Beach Murtha – JDSupra](https://cedclinic.com/irs-section-280e-tax-deductions-cannabis/) Detailed analysis of IRS responses to cannabis industry tax arguments under Section 280E, highlighting ongoing regulatory challenges. [Read More](https://cedclinic.com/irs-section-280e-tax-deductions-cannabis/) [Too many dispensaries? State officials say New York's cannabis market is still growing](https://cedclinic.com/too-many-dispensaries-state-officials-say-new-yorks-cannabis-market-is-still-growing/) Explores the growth and regulatory environment of New York's cannabis market amid increasing dispensary numbers. [Explore Article](https://cedclinic.com/too-many-dispensaries-state-officials-say-new-yorks-cannabis-market-is-still-growing/) [Virginia cannabis sales legalization bill heads to governor (Newsletter: March 16, 2026)](https://cedclinic.com/virginia-cannabis-legalization-impact-healthcare/) Updates on Virginia's legislative progress toward cannabis sales legalization and its implications for the industry. [Learn More](https://cedclinic.com/virginia-cannabis-legalization-impact-healthcare/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).